09.01.14
Vitamin D Could Help Patients With Chronic Hives
Patients with urticaria (chronic hives) who took 4,000 IU of vitamin D3 per day for 12 weeks showed a 40% decrease in Urticaria Symptom Severity (USS) scores, according to research published in the Annals of Allergy, Asthma & Immunology in April.
In this prospective, double-blind, single-center study, 42 subjects with chronic urticaria were randomized to high (4,000 IU/d) or low (600 IU/d) vitamin D3 supplementation for 12 weeks. All subjects were provided with a standardized triple-drug therapy (cetirizine, ranitidine and montelukast) and a written action plan. Data on USS scores, medication use, blood for 25-hydroxyvitamin D and safety measurements were collected.
Results showed triple-drug therapy decreased total USS scores by 33% in the first week. There was a further significant decrease (40%) in total USS scores in the high, but not low, vitamin D3 treatment group by week 12. Compared with low treatment, the high treatment group demonstrated a trend (P = .052) toward lower total USS scores at week 12, which was driven by significant decrease
Patients with urticaria (chronic hives) who took 4,000 IU of vitamin D3 per day for 12 weeks showed a 40% decrease in Urticaria Symptom Severity (USS) scores, according to research published in the Annals of Allergy, Asthma & Immunology in April.
In this prospective, double-blind, single-center study, 42 subjects with chronic urticaria were randomized to high (4,000 IU/d) or low (600 IU/d) vitamin D3 supplementation for 12 weeks. All subjects were provided with a standardized triple-drug therapy (cetirizine, ranitidine and montelukast) and a written action plan. Data on USS scores, medication use, blood for 25-hydroxyvitamin D and safety measurements were collected.
Results showed triple-drug therapy decreased total USS scores by 33% in the first week. There was a further significant decrease (40%) in total USS scores in the high, but not low, vitamin D3 treatment group by week 12. Compared with low treatment, the high treatment group demonstrated a trend (P = .052) toward lower total USS scores at week 12, which was driven by significant decrease
Continue reading this story and get 24/7 access to Nutraceuticals World for FREE
FREE SUBSCRIPTION
